Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 2, facilitated glucose transporter member 12 (SLC2A12)
- Target
- SLC2A12
- Molecular classification
- Transporter, Facilitative glucose transporter, Solute carrier family member
01
Overview
Solute carrier family 2, facilitated glucose transporter member 12 (SLC2A12, also known as GLUT12) is a facilitative glucose transporter belonging to the class III subgroup of the SLC2A family[1][4]. It is widely expressed in human tissues, including skeletal muscle, adipose tissue, small intestine, heart, placenta, mammary tissue, and some cancers[1]. GLUT12 functions as a basal and largely insulin-independent glucose transporter, contributing to glucose uptake in various tissues, but it also serves as a sodium-independent, bidirectional urate transporter[3][5]. Its dysregulation is associated with altered metabolic states, cancer cell glucose metabolism, insulin sensitivity, and hyperuricemia or gout risk[1][3][5].
- Other names
- Glucose transporter type 12GLUT-12GLUT12
02
Mechanism of action
Facilitation of glucose uptake independently of insulin (basal transporter activity); Sodium-independent, bidirectional urate transport
03
Biological functions
Glucose transport across cell membranesFacilitation of glucose uptake in multiple tissuesUrate transport across membranesRegulation of glucose and urate homeostasis
04
Disease associations
Cancer (notably breast and prostate cancer)Hyperuricemia and goutPotential role in Alzheimer's disease (based on altered expression)Cardiovascular disease (suggested by association with glucose metabolism and insulin sensitivity)
05
Safety considerations
Dysregulation may contribute to cancer progression through increased glucose uptake in tumor cellsAltered activity can elevate blood urate levels, increasing risk for gout and hyperuricemiaOverexpression or loss of function could impair glucose or urate homeostasis
06
Biomarkers
Altered expression in certain cancers (e.g., breast and prostate) may serve as biomarker for malignancy or metabolic activityExpression associated with insulin sensitivity/resistance in metabolic disordersElevated expression observed in Alzheimer’s disease tissue
Beyond the preview
Go deeper on Solute carrier family 2, facilitated glucose transporter member 12 (SLC2A12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 12 (SLC2A12).